All posts by medical

Fine-tuning brain activity reverses memory problems in mice with autism mutation – Spectrum

Social circuitry: Mice with an autism-linked mutation have better social memory after treatment that calms a related neural circuit.

Georgejason / iStock

Dampening overactive brain circuits alleviates social and spatial memory problems in a mouse model of 22q11.2 deletion syndrome, according to a new study1. The findings hint at the possibility of novel treatments for some difficulties associated with the syndrome.

Deletions of DNA in a chromosomal region known as 22q11.2 often cause intellectual disability or other cognitive difficulties, as well as psychiatric conditions such as schizophrenia. About 16 percent of people with the deletion also have autism2.

The type and severity of traits vary from person to person, in part because the deletion can span roughly 20 to 50 genes. That range makes it difficult to design targeted therapies. And many people with deletions in 22q11.2 are prone to drug-related side effects, such as seizures.

Side effects with drug treatment is one of the hardest parts of dealing with mental illness, says Julia Kahn, a postdoctoral researcher at the Childrens Hospital of Philadelphia in Pennsylvania, who worked on the study. Being able to circumvent that in a very directed manner would be really life-changing for a lot of people.

The study identifies the neural circuits responsible for select behaviors in model mice and shows that manipulating those circuits could offer a new treatment strategy.

It suggests that therapies can be symptom specific, says lead investigator Douglas Coulter, professor of pediatrics and neuroscience at the University of Pennsylvania in Philadelphia.

Coulter and his colleagues manipulated circuits in two regions of the hippocampus in 22q11.2 model mice: the ventral region, which governs social memory, and the dorsal region, involved in spatial memory. They focused on the hippocampus because it is important to social cognition in both mice and people, and previous studies have shown it is unusually small in people with 22q11.2 deletions3.

Before the manipulation, mice missing 22q11.2 perform worse than controls on tests of their social and spatial memory, the study shows. The mice do not distinguish between a new mouse and one they have already met, and they have trouble recognizing when an object in their cage has been moved. Brain imaging also showed that the model mice have overactive neurons in the hippocampus.

The team used a method known as chemogenetics to dampen this overactivity. They gave the mice an injection that prompts some neurons in the hippocampus to produce designer receptors. They then injected the animals with an experimental drug that binds only to those receptors, making the neurons less excitable.

The animals behaviors changed, depending on where they received the injection. Social memory improved when the drug targeted the ventral hippocampus, and spatial memory improved when the drug affected neurons in the dorsal area. Too much inhibition in either area caused the animals memory problems to return.

Using the same technique, the researchers also gave control mice drug-sensitive receptors that either activate or quell the same circuits in the hippocampus. After both treatments, the controls showed the same social memory problems as the mice with 22q11.2 deletions. The results indicate that disrupting the circuits in either direction is enough to change behavior, even without any underlying genetic mutations. The findings were published in May in Biological Psychiatry.

Chemogenetics is a long way off from use in people, but drugs currently on the market may be able to achieve similar outcomes by nudging circuits into a more balanced state, says Peter Scambler, professor of molecular medicine at University College London in England, who was not involved in the work.

Its a proof of principle, he says.

Manipulating circuits that govern specific behaviors should be a goal of all current work at this point, says Anthony LaMantia, professor of developmental disorders and genetics at Virginia Polytechnic Institute and State University in Blacksburg, who was not involved in the work. This is much more targeted and precise. It should make everybody in the field think through how to design their experiments.

Targeting circuits in the hippocampus could help people, because findings in the hippocampus in mice typically translate well to humans, says Rebecca Piskorowski, head of the synaptic plasticity and neuronal circuits team at the Institute of Psychiatry and Neuroscience of Paris in France, who was not involved in the work.

This kind of targeting might also help at any age. The method improved memory in adult mice, suggesting similar treatments could help older people with 22q11.2 deletions and not just children.

This paper shows if you just adjust the activity in a tiny little place, you can somehow compensate for all those developmental problems, Piskorowski says. That is particularly exciting.

Visit link:
Fine-tuning brain activity reverses memory problems in mice with autism mutation - Spectrum

University of Miami Miller School Plays Pivotal Role in Securing a $15 Million National Alzheimers Disease Research Center – Newswise

Newswise University of Miami Miller School of Medicine investigators play a pivotal role in a consortium of Florida institutions just awarded a $15 million grant to collaborate on Alzheimers disease research.

The five-year National Institutes of Health/National Institute on Aging grant brings together top Florida researchers to focus on better understanding how to diagnose, treat, prevent, and potentially cure Alzheimers in diverse populations.

The 1Florida Alzheimers Disease Research Center, or1Florida ADRC, will be recruiting participants from the University of Miami Miller School of Medicine, the University of Florida, and Mount Sinai Medical Center in Miami Beach. Investigators from these institutions will also be collaborating other Florida academic institutions including Florida Atlantic University and Florida International University.

We are honored that this Alzheimers Disease Research Center is one of 31 centers of excellence designated by the National Institute on Aging. Of the 31 centers in the U.S., the 1Florida ADRC is the only funded center in Florida, said David Loewenstein, Ph.D., ABPP/CN, associate director of 1Florida ADRC and director of the Center for Cognitive Neuroscience and Aging (CNSA) at the Miller School.

Miller School researchers are involved in all aspects of the 1Florida ADRC, including recruitment, onsite evaluation, and research. Dr. Loewenstein is leading the Miller School investigative team. Other UM researchers include Rosie E. Curiel Cid, Psy.D., leader of the1Florida ADRC Outreach, Recruitment and Engagement Core, associate professor and chief, cross-cultural neuropsychology and cognitive neuroscience, in the Center for Cognitive Neuroscience and Aging; Elizabeth Crocco, M.D., chief of geriatric psychiatry and director of UMs state-funded Memory Disorders Clinic and medical director of the CNSA, who will be running the medical aspects of the 1Florida ADRC; and Tatjana Rundek, M.D., Ph.D., professor of neurology and Evelyn F. McKnight Endowed Chair for Learning and Memory in Aging, who is co-leading the ADRCs educational core with Glenn Smith, Ph.D., ABPP/CN, from the University of Florida.

The Miller School is recruiting hundreds of older adults from our local community, said Dr. Loewenstein. Their focus is on engaging African American and Hispanic older adults to make sure they are well represented, because these groups are historically largely under-represented in aging research, including studies looking at Alzheimers disease.

I am the daughter of Cuban exiles; the first to be born in this country. Spanish was my first language. Miami has nurtured this multicultural identity and I am privileged to bring it to the forefront of my work, Dr. Curiel said. One of the greatest challenges in aging research is ensuring that the methods we develop to detect and treat diseases of the aging brain are generalizable toallolder adults. The CNSA is committed to addressing this by developing tools and methods that are cross-culturally applicable. Now, the 1Florida ADRC will significantly broaden our reach. We assembled a passionate team of scientists from diverse cultural backgrounds to engage, educate, listen to, and partner with our richly diverse communities. We hope to generate new knowledge and contribute to national efforts to accelerate clinically meaningful outcomes for older adults and their families.

To better understand diseases of the aging brain, even decades before they occur, the ADRC scientists have an expertise in studying people who dont yet have symptoms but might be concerned about their risk for developing Alzheimers for another reason, such as family history. They also study older adults who may have thinking or memory problems but havent yet been diagnosed, as well as people who have been diagnosed with early mild cognitive impairment.

People in the study will receive annual evaluations including comprehensive neuropsychological testing, a careful clinical examination, an MRI scan of the brain and an amyloid scan, Dr. Loewenstein said. We will follow them on an annual basis.

Dr. Loewenstein and colleagues at the Miller School developed a novel cognitive stress test, called the Loewenstein-Acevedo Scales for Semantic Interference and Learning (LASSI-L) test, which will be used in the 1Florida ADRC study. LASSI-L is a scientifically proven measure that is highly sensitive to early Alzheimers disease brain pathology and can pick up early changes in memory before traditional cognitive testing detects the disease.

The Miller School also stands out for being the only university in the state funded by the NIH to conduct tau imaging. Miller School researchers have a number of federally funded grants that are studying abnormal tau protein in the brain. The presence of amyloid alone is not the only indication of future Alzheimers disease. Some people start to show signs of tau deposition years, even decades, before developing symptoms.

The University of Miami Miller School of Medicine brings something very special to the table and that is why we were asked to be a major part of this initiative. It was because of our strengths in novel cognitive testing, neuroimaging and ability to engage and recruit persons from diverse cultures, Dr. Loewenstein said.

The 1Florida ADRC will also help to train the next generation of scientists in Alzheimers and other neurodegenerative diseases. Dr. Rundek said the ADRCs Research Education Component, called 1Florida Alzheimer's Disease Science Training to Advance Research Success, or AlzSTARS, will train diverse, multidisciplinary early stage investigators at all participating institutions for leadership roles in research translation, especially in regard to diverse and underserved communities.

The AlzSTARS program will provide a unique opportunity for our young trainees from diverse backgrounds to train with clinical and research leaders in Alzheimers disease across Florida and the nation. They will become the next generation of leaders and scientists to successfully translate scientific discoveries to prevention and treatment of Alzheimers disease, Dr. Rundek said.

Dr. Crocco, who has devoted more than 22 years to working with South Floridas older population affected by Alzheimers disease, will also offer her expertise in Alzheimers disease and related disorders to the 1Florida ADRC Clinical Core.

The ADRC brings us to the level of a national center of excellence, Dr. Crocco said. We have the funding and the ability now to be able to promote and really develop more and more these wonderful diagnostic strategies, treatment strategies and, hopefully, one day a cure for Alzheimers disease and other neurodegenerative disorders.

Florida is home to about 12% of the approximately 5.4 million people in the U.S. who have Alzheimers disease. For more information about 1Florida ADRC including how to participate, visitwww.1floridaadrc.org, emailinfo@1floridaadrc.orgor call 352-273-7425 or 305-355-9080.

Continued here:
University of Miami Miller School Plays Pivotal Role in Securing a $15 Million National Alzheimers Disease Research Center - Newswise

BioXcel Therapeutics Announces Notice of Allowance for US Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationPatent…

NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 16/453,679 related to BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex). The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations.

The allowance of this patent substantially strengthens our intellectual property position, an important milestone for BXCL501s development and potential commercialization, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. With a significant need for an effective therapy that addresses the underlying cause of agitation, BXCL501 has the potential to fill this gap, while also providing a unique and favorable delivery method for treating patients. As we prepare to report topline data from our pivotal SERENITY trials this month, we are thrilled to have received this patent allowance for film formulations containing Dex, an essential step in creating value for our shareholders.

A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted from an application. The patent, which is expected to be issued in the third quarter of 2020, will have a term that expires no earlier than 2039. After issuance, BioXcel plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

About BXCL501

BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in the Phase 1b/2 TRANQUILITY trial for the treatment of agitation associated with dementia, as well as the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to receipt of patent approval for BXCL501, the Companys intellectual property strategy, the timing and data from clinical development initiatives and trials for BXCL501, the potential commercialization of BXCL501 and BTIs corporate strategy. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

These forward-looking statements are based on managements current expectations and beliefs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause BTIs actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BTIs product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and Investors sections of our website at http://www.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

Contact Information:BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Read more from the original source:
BioXcel Therapeutics Announces Notice of Allowance for US Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationPatent...

Infertile couples overestimate their chance of IVF success – BioNews

7 July 2020

Couples undergoing fertility treatment markedly overestimate their chance of IVF success, men to a greater extentthan women, according to new research.

The research presented at the virtual meeting of the European Society of Human Reproduction and Embryology 2020 came from a small, single-centre study at Leuven University fertility clinic in Belgium.

'Clinics do share average success rates on their websites, but these are often only relevant to a reference population of younger patients. And many patients do not think that average success rates apply to them. They expect greater success, thinking of their healthy lifestyle or their experienced doctors,' said study author embryologist Johanna Devroe.

Sixty-nine couples who were about to start at second or subsequent IVF cycles separately completed a questionnaire assessing their dispositional outlook and estimated their chances of IVF success. The data was then compared with the couples' personalised calculated chance of IVF live birth.

The mean calculation of live birth rate for participants in the study was 32 percent, however, the vast majority of both women and men greatly overestimated their chances of success. Women overestimated by a factor of 1.8, while men overestimated their chance of success by a factor of 2.3 with over halfof the men expecting their birth rate to be more than double their calculated prognosis.

'Partners didn't differ in their dispositional outlook so we cannot fully explain the higher expected live birth rate in men by a difference in optimism,' said Devroe. 'We are now investigating this, to see if disclosing an individual's predicted success rate rather than a clinic's average success rate helps to set realistic expectations.'

Sarah Norcross, director of fertility and genetics charity, the Progress Educational Trust, said: 'This interesting, though not surprising, single-centre study, shows just how much both men and women hoping to become parents overestimate their chances of success following fertility treatment. It sends an important message to fertility clinics about the need to manage patients' expectations and support them before, during and after fertility treatment. The dramatic mismatch shown by this study where the vast majority of both men and women estimated their chance of success to be double what it actually was shows just how shocking it can be for couples when IVF does not work which is, sadly, what happens two-thirds of the time.'

Dr Raj Mathur, consultant gynaecologist and fertility lead at St Mary's hospital, Manchester, told BioNews: 'The findings will resonate with members of the British Fertility Society, who aim to counsel patients properly about their individual chances, while at the same time recognising the innate human bias towards positivity and hope. We support clinics and the UK fertility regulator, the Human Fertilisation and Embryology Authority in displaying success rates in a uniform way that can be understood by patients, and we feel that the relationship between patients and their clinicians is of the utmost importance in making decisions about whether to start or continue complex fertility treatment.'

The rest is here:
Infertile couples overestimate their chance of IVF success - BioNews

New practical recommendations for the use of time-lapse technology in ART – ESHRE

New recommendations from ESHRE concentrate on the practicalities of introducing a time-lapse system into IVF labs, not on its use solely to improve delivery rates.

Despite such hopes and its widespread uptake, a lack of good practice guidelines for TLT in IVF has persisted. Now, the wait is over. Debbie Montjean, a member of the ESHREs SIG Embryology and one of 11 international contributors, presented details of the long awaited recommendations for TLT at this years virtual annual meeting. The collaborative effort has now produced a set of good-practice recommendations for the introduction and application of TLT, a comprehensive literature review and detailed time points for annotating development, whilst finely balancing both the pros and cons of this technology.(1)

The published recommendations, as Montjean emphasised, are not set out as a blueprint for improving embryo selection or delivery rates, but provide extensive support to IVF laboratories embarking on investment in TLT and standardisation and structure to those with the systems already in place. In addition, the publication emphasises the need for consistent nomenclature and annotations of morphokinetics, guidelines which were previously published but further summarised within this publication.(2)

For newcomers to the technology the recommendations are divided into a user-friendly 11-step guide to the best approach to introduction and application. The publication comprehensively reviews all versions of TLT currently available, comparing an extensive range of user requirement specifications in hardware, software and the on-going costs of technical support and maintenance.

Acknowledging the initial excitement when TLT was first introduced, with obvious implications for the efficiency of ART treatment, the authors propose that these expectations are yet to be met; indeed, the integration of TLT within the ART laboratory has not yet increased IVF success rates as once hoped. Yet, added Montjean, clinical outcomes arent the only advantage to justify use. Significant importance to other laboratory activities should not be ignored, she said. Undisturbed and stable culture conditions combined with improvements in laboratory workflow, flexibility and efficiency are substantial benefits. Moreover, TLT has undoubtedly revealed further biological markers and development anomalies which are otherwise undetected in traditional culture and static embryo assessments. Thus, the recommendations summarise 20 atypical features in human embryo cleavage development, 13 of which are exclusively observed using TLT and the remaining seven better observed when assisted by TLT. Such observations of subtle embryo anomalies and early mitosis can assist in blastocyst prediction with higher sensitivity and accuracy. Montjean ended her online presentation noting that time-lapse will at least help you to prioritise embryos and ultimately shorten your time to pregnancy.

Until now the absence of good practice guidelines for TLT and a lack of standardisation might be a reason for the inconsistent results among global users of the technology. But the authors here recognise that TLT is here to stay in the IVF lab; perhaps a standardisation of practice may unify the data and point towards an improvement in IVF success rates.

1. ESHRE Working group on Time-Lapse technology. Good practice recommendations for the use of time-Lapse technology. Hum Reprod Open 2020; doi: 10.1093/hropen/hoaa008.2. Ciray HN, Campbell A, Agerholm AE, et al. Proposed guidelines on the nomenclature and annotation of dynamic human embryo monitoring by a time lapse user group. Human Reprod 2014; 29: 2650-2660.

Read the original here:
New practical recommendations for the use of time-lapse technology in ART - ESHRE

"The global gold standard": Aussie startup Presagen launches its AI fertility app in the UK and Europe – SmartCompany.com.au

Co-founders Dr Jonathan Hall, Dr Michelle Perugini and Dr Don Perugini. Source: Matt Loxton.

An Australian company that uses artificial intelligence to increase the chance of pregnancy through IVF has launched its software application in the UK and Europe.

Life Whisperer, the fertility arm of AI healthcare company Presagen, commercialised its flagship product in Australia in late January and released it through a distributor into India, Sri Lanka and Bangladesh last month.

Approvals are also being sought to sell the South Australian-developed software tool in Japan, Southeast Asia and the US, where it has conducted a number of clinical trials.

Last weeks launch into the UK and Europe is a major step in the three-and-a-half-year journey for the product, which was forced into a COVID-19 hiatus from March to May when many of the worlds fertility clinics closed their doors.

Adelaide-based Presagen currently has 15 staff and small offices in San Francisco and London to drive the global expansion.

Get COVID-19 news you can use delivered to your inbox.

Youll also receive special offers from our partners. You can opt-out at any time.

Presagen co-founder and chief executive Dr Michelle Perugini said the company had strong connections in the UK and Europe and a number of clinics were already trialling the product in the region.

She said getting clinics on board as commercial customers was the next stage.

Regulatory approval in the UK and Europe represents a significant opportunity for Life Whisperer to expand its global presence, and we are very much looking forward to working with clinics and patients across the region, supported from our London offices, she said.

Its a secure web-based application that is completely scalable so we can set up new clinics within minutes anywhere in the world.

The Embryo Viability Application for IVF clinics uses artificial intelligence to analyse images of embryos to assist clinicians to identify which embryo will likely lead to a pregnancy.

By selecting the best embryo, Life Whisperer aims to shorten the time to pregnancy and improve outcomes for couples undergoing IVF treatment.

An international study recently published in the journal Human Reproduction involved blind evaluation of 1600 IVF embryos.

Life Whisperer was shown to perform 25% better than traditional manual methods of embryo assessment by highly experienced embryologists.

The technology was showcased on Tuesday night last week (Australian time) at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology, which is being held online this year.

Internationally renowned fertility expert Matthew (Tex) VerMilyea from Ovation Fertility (US) will present Life Whisperers latest advances in AI for IVF at the event where Presagen will also have a virtual exhibition booth.

Dr Perugini said Presagen was planning a significant capital raise this year to drive growth.

She said the company was looking forward to working with IVF clinics across the globe to offer Life Whisperer to patients at a low cost, meaning more couples could gain more certainty in embryo selection and achieve success sooner, with fewer IVF cycles.

Life Whisperer is poised to become the global gold standard embryo pre-screening tool in IVF, supporting the clinical decision about which embryo is most viable.

This article was first published by The Lead.

NOW READ: Billions in lost revenue, 10,000 jobs lost: How COVID-19 will undermine Australias research capacity

NOW READ: The healthcare industry is buckling under pressure and ripe for disruption, says AirTree investor Jackie Vullinghs

Small and medium businesses and startups have never needed credible, independent journalism and information more than now.

Thats our job at SmartCompany: to keep you informed with the news, interviews and analysis you need to manage your way through this unprecedented crisis.

Now, theres a way you can help us keep doing this: by becoming a SmartCompany supporter.

Even a small contribution will help us to keep doing the journalism that keeps Australias entrepreneurs informed.

Go here to see the original:
"The global gold standard": Aussie startup Presagen launches its AI fertility app in the UK and Europe - SmartCompany.com.au

Risk of IVF babies being born with cerebral palsy halves due to decline in twins, study reveals – The Telegraph

The risk of IVF babies being born with cerebral palsy has fallen by 50 per cent due to the decline in twins, a study has found.

Fewer twins are being conceived using the method because doctors are reducing the practice of implanting multiple embryos into the woman's womb, according to scientists at Copenhagen University Hospital in Denmark.

Women who have just one embryo transferred during IVF treatment are five times more likely to give birth to a healthy baby as there is less risk the child will be born low-weight or delivered prematurely, researchers from the University of Aberdeen previously found.

IVF twin rates have declined from almost 25 per cent in the 1990s to less than 5 per cent today.

This latest study now indicates that the number of babies being born with cerebral palsy, a condition which affects movement and coordination, has more than halved in the past 20 years and the risk is now equal to those conceived naturally.

Using data from Denmark, Finland and Sweden, the researchers examined some 112,000 IVF children born over 24 years.

They found that the prevalence of cerebral palsy among single babies born from IVF decreased from 8.5 per 1,000 to the normal population rate of 2.8. For twins, the rate remained stable at 10.9.

Dr Anne Lrke Spangmose presented the findings at the online Annual Meeting of the European Society of Human Reproduction and Embryology.

"The inclusion of complete IVF and naturally conceived birth cohorts makes our data robust and has allowed assessment of the true risk of cerebral palsy in IVF and its decline over time," she said.

"Multiple embryo transfer is still standard care in many countries. Our findings emphasise that single embryo transfer and singleton births should be encouraged worldwide."

Large registry studies have shown that the risk of cerebral palsy has virtually disappeared in IVF children born in the Nordic countries after a policy of single embryo transfer was introduced in the early 2000s.

The NHS recommends that women aged 39 and under should have a single embryo transfer where possible, while women aged 40 and above can have a double embryo transfer.

See the original post:
Risk of IVF babies being born with cerebral palsy halves due to decline in twins, study reveals - The Telegraph

I found sperm donor on Facebook as I was desperate for a baby, we first met when he came round to give me the – The Sun

A FIRST-TIME mum was so desperate to have a child with her female partner that she used aspermdonor - that she found on FACEBOOK.

Shannon, 20, turned to the social networking site in the hope of finding an affordable way to fall pregnant with her partner, Katie, 25.

6

The pair began to research their options, but didn't like the idea of picking an anonymous donor from a list and couldn't afford the 3k fertility clinic price tag.

Instead, they joined a Facebook group with other hopeful parents and willing donors.

They went on to select a donor from Facebook in April 2019, after being together for seven months, and within two months Shannon fell pregnant via artificial insemination (AI) - using a syringe bought from Amazon to conceive.

Artificial insemination is the process in which a donor'sspermis inserted into the female's body not via sex - but commonly with pipettes and even turkey basters.

6

She gave birth to Ocean Mabel Rose onFebruary 13 this year, weighing a healthy 6lbs 2oz - their first baby together.

Ocean completes their new family of four - as Katie has another child also via a donor, two-year-old Jaycee-Rayne.

Stay-at-home mum Shannon said: "I'm adopted myself, and have never been surrounded by an actual biological family.

"Once Katie and I decided we wanted a baby together, I simply searched online 'Spermdonors UK'.

"I wasnt expecting much, perhaps to see a load of IVF clinics with all these huge prices that I knew I would never be able to afford.

I got lots of strange friend requests from men saying they would be my donor, but 8/10 looked like fake accounts.

"Instead, it linked me to a Facebook group where donors and recipients could find each other and get to know one another - establishing a proper relationship, not all anonymous like the clinics do things.

"I was shocked at first as I thought it was odd. But the more I looked into it, the more I warmed up to the idea.

"Everyone was friendly and we had so many donors messaging us and offering their services. If I was to have another child, this is the only way I'd do it."

New mum Shannon had always dreamed of having her own baby, but knew the costs atspermdonor clinics were out of her budget.

She said: "Ever since I was a kid I wanted to be a mum.

6

"Having a female partner automatically made that process more difficult, but it was just another hurdle to overcome.

"I'd considered aspermdonor in December 2018 when I was single, but then Katie came into my life and things changed."

Meeting on dating app Plenty of Fish, Shannon and full-time-mum Katie instantly clicked and discussed having their own children. Katie was already a mother to then 10-month-old Jaycee-Rayne.

Shannon said: "I expressed to Katie that I wanted to have a child but she wasnt ready at that time, considering how young her daughter was.

"By January 2019 I brought the subject back up and it nearly broke our relationship as she still wasn't ready.

6

"Having a baby was my number one dream, but she had already had her daughter and just wasnt ready to take on another."

Two months later, the couple had another chat, and after some tears and a deep discussion, they decided that they were ready to have a baby of their own.

Unsure where to commence their search for aspermdonor, the pair searched online on a whim for options, and Facebook was the first result that popped up.

The link was to a private Facebook group of hopeful parents andspermdonors offering their services.

Shannon said: "There were hundreds of groups, but I wanted to make sure I wasnt rushing into joining any old one.

The donor really understood the process, and was patient with us without being overbearing or creepy.

"I worried about the motives of some of these donors, but once we saw their STD checks and genetic test results, my mind was put at ease.

"Looks weren't too important to us either, as the DNA pool would be 50/50 anyway. We were more concerned about having a healthy, happy baby over anything cosmetic.

"At first I got lots of strange friend requests from men saying they would be my donor, but 8/10 looked like fake accounts.

"But then I saw more and more posts from women who had been successful with their donors, and it gave me the hope that the right donor would eventually come to me."

In April 2019 Shannon and Katie received the message they had been waiting for - a donor who had previously fathered children through the page.

He provided them with up-to-date health check certificates, photos of himself, his job description and photos of his previous donor children -of which there were 11.

6

Excited Katie said: "I practically jumped with excitement and thought to myself that he was perfect, and the one for us.

"Once we started talking, Shannon let him know the dates on which she would be ovulating, so he could come to our flat in that time-frame and provide hissperm.

"We bought a kit on Amazon which came with an ovulation test, a sterile cup for the donor to leave his sample in, and a syringe so I could insert Shannon with thespermonce the donor had completed his sample."

The donor then came to the pair's flat two times in May and June, taking his sample cup into the bathroom to fill withspermand return it to the couple.

Then, Katie would suck up thespermwith a syringe and insert it into Shannon, who lay down for at least half an hour to ensure thespermwas in her body.

Shannon said: "It was all a bit of a rush, as to maximise the chance of falling pregnant thespermshouldn't be outside of the body for too long. After about 20 minutes thespermcan die, so we couldn't afford to wait if we wanted it to be successful.

"The donor really understood the process, and was patient with us without being overbearing or creepy.

"He said he did it to help women or couples have children he just seemed like a nice man, and always did the job!"

The couple paid the donor's transport costs, and although DIY insemination is not officially unlawful, it is illegal to distributespermintended for human application without a licence issued by theHuman Fertilisation and Embryology Authority.

Donors on Facebook dont have the same rights as theofficial route theyre liable to pay child support if a contract isnt signed and could still see the child if thats what both parties want.

After two attempts, Shannon successfully became pregnant in June 2019."I had such severe morning sickness until week 25 of the pregnancy, but I was elated more than anything to have a safe and healthy baby," she said.

"Our little girl was born naturally at 38 weeks and it was the best day of my life."

6

Shannon was in labour for 16 hours, and with Katie by her side she gave birth on 13th February 2020 to Ocean Mabel Rose.

Shannon said: As soon as I held my baby I knew Id made the right decision. Katie and I were both in tears, and I felt nothing but pure joy. She looked perfect."

There is no fathers name on Ocean's birth certificate and a man who providesspermas a donor gives up his legal rights over the biological child.

The donor will only meet the baby at the request of Shannon and Katie, but he has no legal grounds upon which to request visitation or custody.

Shannon said: "I feel like a new woman.

"We're all doing really well, and Ocean is the most content baby ever.

"The process was so easy and we were so lucky to fall pregnant so quickly.

"We now have the perfect family of four. Facebook gave me a baby, something I never thought I'd say."

How does sperm donation in the UK work?

Sperm donation can help couples struggling to have kids of their own or single women who want to start a family.

If you donate your sperm through a fertility clinic or a sperm bank, you wont have any responsibilities or rights towards a child conceived using your semen.

However, as of April 2005, children conceived through sperm donation do have the right to ask for certain information about their donor once they reach the age of 16.

When they turn 18 they can also request to know the name and last known address of their donor.

The main reason men choose to donate their sperm is to help couples who cant conceive naturally, or if they have a strong desire to pass on their genes to another generation.

In the UK, donation in exchange for payment is prohibited by law.

SUPERMARKET SWEEPMum shares meal planner which has saved her family 360 a month on food

Exclusive

HINCH ITMy entire home is grey just like Mrs Hinch's - we even have the same dog

REPLI-KATELidl is selling a 9.99 dress which is identical to Kate Middletons 449 frock

HOME RUNMum beats empty nest syndrome by making daughter's room a MASSIVE walk-in wardrobe

SPEND A PENNYMums show off their TX Maxx and Wilko bargains including 1p school supplies

CRUSHED ITWoman wanted 360 crushed diamond table so made one using The Range coasters

Meanwhile, super sperm donorMitch KennedybaffledThis Morning viewerswith his plan to prevent incestuous relationships among his expanding brood.

And 66 kids and counting... 'white van man sperm donor' Clive tells more about his remarkable storyhere.

Plus meet Charlotte who had a kid with Clive - one of the UK's most prolific sperm donors.

Read the original post:
I found sperm donor on Facebook as I was desperate for a baby, we first met when he came round to give me the - The Sun

Simple hair test ‘could tell women how many eggs they have left’ – Brinkwire

A simple test of a womans hair could tell women how many eggs they have left by judging levels of a key fertility hormone, scientists say.

US and Spanish researchers found biologically relevant levels of anti-Mllerian hormone (AMH) an indicator of ovarian reserves in womens hair samples.

AMH is a hormone produced by the cells within a womans ovaries and gives an indication of her egg reserves and subsequent fertility.

The hormone is incorporated into the matrix of hair before it reaches the surface of the skin.

Levels of AMH from the hair correlated with levels from blood samples, which is currently the most common method of measuring the hormone.

But taking AHM readings from the hair would be less invasive than a blood sample and a more appropriate representation of hormone levels, according to scientists.

Testing can be done without visiting a clinic, such as by sending a hair sample through the post, which makes this type of test cheaper and available to a broader range of women.

The role of AMH as a measure of ovarian reserve in predicting response to ovarian stimulation for IVF now seems beyond question, researchers add.

Hair is a medium that can accumulate biomarkers over several weeks, while serum is an acute matrix representing only current levels, said Sarthak Sawarkar at US health tech firm MedAnswers, who presented his research online at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology.

While hormone levels in blood can fluctuate rapidly in response to stimuli, hormone levels measured in hair would represent an accumulation over several weeks.

A measurement using a hair sample is more likely to reflect the average hormone levels in an individual.

AMH has become a key marker in the assessment of how women may respond to fertility treatment.

The hormone is produced by small cells surrounding each egg as it develops in the ovary.

Studies have not correlated AMH levels to a reliable chance of live birth, nor to forecasting the time of menopause.

However, AMH measurement has become an intrinsic marker in assessing how a patient will respond to ovarian stimulation for IVF as a normal responder, poor responder (with few eggs), or over-responder (with many eggs and a risk of ovarian hyperstimulation syndrome).

Currently, AMH is presently measured in serum taken from a blood sample drawn intravenously, but readings taken this way represent just a snapshot of a moment in time and are relatively invasive to complete.

To learn more about the potential of AMH readings taken from the hair, researchers collected hair and blood samples 152 women from whom hair were during hospital visits.

AMH was also measured in blood samples from the same subjects, as well as an ultrasound count of developing follicles in the ovary a method known as antral follicle count (AFC).

Biologically relevant AMH levels were successfully detected in the hair samples, which declined with patient age, as expected by the team.

AMH levels from hair strongly correlated with levels as determined by both serum in the blood and AFC.

The hair test was also able to detect a wide range of AMH levels within individuals from a similar age cohort, suggesting a greater accuracy than from a single blood sample.

Hormones accumulate in hair shafts over a period of months, while hormone levels in serum can change over the course of hours, they found, meaning the hair test may be a more reliable measurement.

Hormone levels are also assessed non-invasively, which reduces testing stress and offers a less expensive assay.

This study is very interesting as it suggests AMH can be reliably measured from hair samples as opposed to the standard approach of a blood test, Tim Child, medical director at Oxford Fertility, told the Times.

The AMH level in hair is more likely to be averaged-out over a time period rather than the more instant level in a blood sample.

The question is whether the hair AMH levels correlate to the ovarian response and therefore numbers of eggs collected during an IVF cycle this is not examined in this study.

If the correlation is poor then hair samples will be of no benefit.

If the correlation is as good as, or perhaps even better than with blood AMH, then this technique promises to further simplify the fertility treatment process for women and will be an exciting development.

The results have been presented by PhD student Sarthak Sawarkar, working in the laboratory of Professor Manel Lopez-Bejar in Barcelona, with collaborators from MedAnswers.

See more here:
Simple hair test 'could tell women how many eggs they have left' - Brinkwire

Comparative Anatomy and Histology | ScienceDirect

Comparative Anatomy and Histology: A Mouse and Human Atlas is aimed atthe new mouse investigator as well asmedical and veterinarypathologists who need to expand their knowledge base into comparative anatomy and histology. It guides the reader through normal mouse anatomy and histology using direct comparison to the human. The side by side comparison of mouse and human tissues highlight the unique biology of the mouse, which has great impact on thevalidation of mouse modelsof human disease.

Link:
Comparative Anatomy and Histology | ScienceDirect